Literature DB >> 7122112

Plasma morphine concentrations during chronic oral administration in patients with cancer pain.

Palle B Neumann1, Hans Henriksen, Nina Grosman, Christian Broen Christensen.   

Abstract

Plasma concentrations of morphine were studied in 16 patients with chronic pain due to advanced cancer, treated with regular doses of morphine chloride by the oral route. Doses ranged from 20 to 125 mg every 4 h and a significant, positive, linear correlation was found between dose (range 0.22-3.01 mg/kg) and mean plasma concentration (range 22-364 ng/ml). The profile of the 4 h concentration curve is described and found to be subject to considerable, individual variation. The present investigation supports the experience that good pain relief can be obtained, if individual requirements as to dose and dose interval are taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7122112     DOI: 10.1016/0304-3959(82)90014-8

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  11 in total

1.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

Authors:  Andrew A Somogyi; Mie Larsen; Reza M Abadi; Jaroon Jittiwutikarn; Robert Ali; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 3.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

4.  Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.

Authors:  J Säwe; L Kager; J O Svensson Eng; A Rane
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

5.  Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Authors:  Patrick A Singleton; Nurbek Mambetsariev; Frances E Lennon; Biji Mathew; Jessica H Siegler; Liliana Moreno-Vinasco; Ravi Salgia; Jonathan Moss; Joe Gn Garcia
Journal:  J Angiogenes Res       Date:  2010-02-19

Review 6.  Newer methods of delivery of opiates for relief of pain.

Authors:  P J Slattery; R A Boas
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

Review 7.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.

Authors:  A A Somogyi; R L Nation; C Olweny; P Tsirgiotis; J van Crugten; R W Milne; J F Cleary; C Danz; F Bochner
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

9.  Antinociceptive activity of Stephanolepis hispidus skin aqueous extract depends partly on opioid system activation.

Authors:  Vinicius Carvalho; Lohengrin Fernandes; Taline Conde; Helena Zamith; Ronald Silva; Andrea Surrage; Valber Frutuoso; Hugo Castro-Faria-Neto; Fabio Amendoeira
Journal:  Mar Drugs       Date:  2013-04-10       Impact factor: 5.118

10.  Therapeutic concentration of morphine reduces oxidative stress in glioma cell line.

Authors:  M B Almeida; A Costa-Malaquias; J L M Nascimento; K R Oliveira; A M Herculano; M E Crespo-López
Journal:  Braz J Med Biol Res       Date:  2014-05-02       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.